Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Allakos Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2012-01-01

Employees: 131

Market Cap: $62.1M

Website: http://www.allakos.com

Clinical Trials

Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001

Phase 1

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: AK006 IV

First Posted Date: 2024-08-29

Last Posted Date: 2025-06-03

Lead Sponsor: Allakos Inc.

Target Recruit Count: 29

Registration Number: NCT06577116

Locations: 🇨🇦
Site 601-106, Calgary, Alberta, Canada
🇺🇸
Site 601-004, Birmingham, Alabama, United States
🇺🇸
Site 601-014, Bakersfield, California, United States

and more 11 locations

Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria

Phase 1

Completed

Conditions: Healthy Participants
Chronic Spontaneous Urticaria

Interventions: Drug: AK006-IV
Drug: AK006-SC
Drug: Placebo-IV
Drug: Placebo-SC

First Posted Date: 2023-10-10

Last Posted Date: 2025-06-03

Lead Sponsor: Allakos Inc.

Target Recruit Count: 136

Registration Number: NCT06072157

Locations: 🇺🇸
Site 601-001 Healthy Volunteer Clinical Research Unit (Part A, B and D), Anniston, Alabama, United States
🇺🇸
Site 601-004 (Part C), Birmingham, Alabama, United States
🇺🇸
Site 601-008 (Part C), Scottsdale, Arizona, United States

and more 22 locations

A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

Phase 2

Terminated

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: Lirentelimab (AK002)
Other: Placebo

First Posted Date: 2022-09-06

Last Posted Date: 2024-06-06

Lead Sponsor: Allakos Inc.

Target Recruit Count: 127

Registration Number: NCT05528861

Locations: 🇺🇸
Allakos Investigational Site 227-024, Birmingham, Alabama, United States
🇺🇸
Allakos Investigational Site 227-068, Cullman, Alabama, United States
🇺🇸
Allakos Investigational Site 227-014, Phoenix, Arizona, United States

and more 63 locations

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis

Phase 2

Terminated

Conditions: Atopic Dermatitis

Interventions: Other: Placebo
Drug: AK002

First Posted Date: 2021-12-13

Last Posted Date: 2024-10-15

Lead Sponsor: Allakos Inc.

Target Recruit Count: 131

Registration Number: NCT05155085

Locations: 🇺🇸
Allakos Investigational Site 218-034, Birmingham, Alabama, United States
🇺🇸
Allakos Investigational Site 218-074, Cullman, Alabama, United States
🇺🇸
Allakos Investigational Site 218-025, Gilbert, Arizona, United States

and more 52 locations

A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Phase 3

Withdrawn

Conditions: Eosinophilic Gastritis
Eosinophilic Duodenitis

Interventions: Other: Placebo
Drug: AK002

First Posted Date: 2021-12-10

Last Posted Date: 2023-03-03

Lead Sponsor: Allakos Inc.

Registration Number: NCT05152563

Locations: 🇺🇸
Allakos Investigational Site, Seattle, Washington, United States

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis

Phase 3

Completed

Conditions: Eosinophilic Duodenitis
Eosinophilic Gastroenteritis

Interventions: Other: Placebo
Drug: AK002

First Posted Date: 2021-04-23

Last Posted Date: 2024-01-02

Lead Sponsor: Allakos Inc.

Target Recruit Count: 94

Registration Number: NCT04856891

Locations: 🇺🇸
Allakos Investigational Site, Fredericksburg, Virginia, United States

An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Phase 3

Completed

Conditions: Eosinophilic Duodenitis
Eosinophilic Gastritis

Interventions: Drug: lirentelimab

First Posted Date: 2020-11-09

Last Posted Date: 2024-04-22

Lead Sponsor: Allakos Inc.

Target Recruit Count: 159

Registration Number: NCT04620811

Locations: 🇺🇸
Allakos Investigational Site 216-068, Birmingham, Alabama, United States
🇺🇸
Allakos Investigational Site 216-002, Huntsville, Alabama, United States
🇺🇸
Allakos Investigational Site 216-035, Phoenix, Arizona, United States

and more 35 locations

A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers

Phase 1

Completed

Conditions: Study Conducted in Healthy Volunteers

Interventions: Drug: lirentelimab (AK002)
Other: Placebo

First Posted Date: 2020-03-27

Last Posted Date: 2023-04-18

Lead Sponsor: Allakos Inc.

Target Recruit Count: 66

Registration Number: NCT04324268

Locations: 🇺🇸
Allakos Investigational Site, Edgewater, Florida, United States

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Phase 3

Completed

Conditions: Eosinophilic Gastritis
Eosinophilic Duodenitis

Interventions: Other: Placebo
Drug: lirentelimab (AK002)

First Posted Date: 2020-03-26

Last Posted Date: 2024-01-02

Lead Sponsor: Allakos Inc.

Target Recruit Count: 181

Registration Number: NCT04322604

Locations: 🇺🇸
Allakos Investigational Site, Spokane, Washington, United States

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

Phase 2

Completed

Conditions: Eosinophilic Esophagitis

Interventions: Drug: lirentelimab (AK002)
Other: Placebo

First Posted Date: 2020-03-26

Last Posted Date: 2024-01-02

Lead Sponsor: Allakos Inc.

Target Recruit Count: 277

Registration Number: NCT04322708

Locations: 🇳🇱
Allakos Investigational Site, Amsterdam, North Holland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy